Evidence map›Paper›PMID 42321789›Full record

ArticleJournal of nanobiotechnology2026

Cross-species hybrid vesicles enable synergistic immunochemotherapy through enhanced targeted drug delivery and immune activation.

Zhou Fang, Saichao Wei, Shaoqian Wang, Jiaqi Xu, Min Zhang, Mingyu Yin, Jun Wang, Kehai Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhou FangDepartment of Biopharmaceutical Science, Shanghai Ocean University, Hucheng Ring Road, Shanghai, China.
Saichao WeiDepartment of Biopharmaceutical Science, Shanghai Ocean University, Hucheng Ring Road, Shanghai, China.
Shaoqian WangDepartment of Biopharmaceutical Science, Shanghai Ocean University, Hucheng Ring Road, Shanghai, China.
Jiaqi XuDepartment of Biopharmaceutical Science, Shanghai Ocean University, Hucheng Ring Road, Shanghai, China.
Min ZhangDepartment of Biopharmaceutical Science, Shanghai Ocean University, Hucheng Ring Road, Shanghai, China.
Mingyu YinDepartment of Biopharmaceutical Science, Shanghai Ocean University, Hucheng Ring Road, Shanghai, China.
Jun WangSchool of Medicine, The International Peace Maternal and Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China. Wangjun200408@aliyun.com.
Kehai LiuDepartment of Biopharmaceutical Science, Shanghai Ocean University, Hucheng Ring Road, Shanghai, China. khliu@shou.edu.cn.

Funding

National Natural Science Foundation of China 82172796, 82373277
6 · The paper itself

Abstract

To overcome the critical challenges of insufficient drug targeting and restricted dendritic cell (DC) activation in chemo-immunotherapy, this study developed an innovative cross-species hybrid vesicle delivery system. By fusing extracellular vesicles derived from 4T1 tumor cells (TEV) with kiwifruit-derived extracellular vesicles (KEV), we constructed a homologous targeting hybrid vesicle carrier (TKEV). This platform was co-loaded with chemotherapeutic agent doxorubicin (DOX) and Bcl-2 siRNA (siBcl2) to form a combination therapeutic system (TKDS). Key findings demonstrate: (1) TKDS achieves precise tumor-targeted delivery, significantly enhancing tumor cell apoptosis through combined chemo-gene therapy; (2) The KEV component effectively stimulated DC maturation, enhanced antigen presentation, and increased CD8

Indexed as

Drug Delivery SystemsExtracellular VesiclesImmunotherapyAnimalsAntineoplastic AgentsApoptosisCell Line, TumorDendritic CellsDoxorubicinFemaleMiceMice, Inbred BALB CProto-Oncogene Proteins c-bcl-2RNA, Small InterferingAntineoplastic AgentsDoxorubicinProto-Oncogene Proteins c-bcl-2RNA, Small InterferingCombination therapyDC maturationHybrid vesiclesImmunochemotherapyTargeting

Identifiers

PMID42321789
PMCPMC13528136

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.